Hydroxychloroquine shortened hospital stay and reduced intensive care unit admissions in hospitalized COVID-19 patients.


Journal

Journal of infection in developing countries
ISSN: 1972-2680
Titre abrégé: J Infect Dev Ctries
Pays: Italy
ID NLM: 101305410

Informations de publication

Date de publication:
31 Jan 2022
Historique:
received: 19 02 2021
accepted: 09 05 2021
entrez: 22 2 2022
pubmed: 23 2 2022
medline: 26 2 2022
Statut: epublish

Résumé

Effectiveness of hydroxychloroquine against SARS-CoV-2 has been highly controversial. In our research, we aimed to investigate the effects of hydroxychloroquine on disease outcomes in hospitalized patients with COVID-19. A total of 393 hospitalized patients with COVID-19 were retrospectively assigned to the standard of care therapy group (n = 180) or the standard of care plus hydroxychloroquine group (n = 213). The standard of care therapy comprised favipiravir, low molecular weight heparin, acetylsalicylic acid. Status of oxygenation at baseline and on the seventh day, laboratory tests at baseline and at discharge were recorded. Length of hospital stay, administration of anti-inflammatory treatment, admission to the intensive care unit and 28th day mortality were set as primary endpoints. There were no statistically significant differences between groups in terms of oxygen delivery route and mortality after seven days of treatment (p = 0.592). C-reactive protein levels of the standard of care plus hydroxychloroquine group were significantly lower than that of the standard of care group at discharge (p = 0.034). Patients in the standard of care plus hydroxychloroquine group had shorter hospital stay (p = 0.007). The standard of care plus hydroxychloroquine group was favored over standard of care group in terms of rate of intensive care unit admissions (21.7% vs. 10.8%; relative risk with 95% CI = 0.49 [0.31-0.80], p = 0.003). Hydroxychloroquine in addition to standard of care was associated with less intensive care unit admissions, early discharge and greater C-reactive protein reduction. There was no difference in 28-day mortality.

Identifiants

pubmed: 35192518
doi: 10.3855/jidc.14933
doi:

Substances chimiques

Hydroxychloroquine 4QWG6N8QKH

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

25-31

Informations de copyright

Copyright (c) 2022 Ahmet Omma, Abdulsamet Erden, Hakan Apaydin, Meryem Aslan, Huseyin Camli, Enes Seyda Sahiner, Serdar Can Guven, Berkan Armagan, Selma Karaahmetoglu, Ihsan Ates, Orhan Kucuksahin.

Déclaration de conflit d'intérêts

No Conflict of Interest is declared

Auteurs

Ahmet Omma (A)

Department of Internal Medicine, Division of Rheumatology, Ankara City Hospital, Ankara, Turkey.

Abdulsamet Erden (A)

Department of Internal Medicine, Division of Rheumatology, Ankara City Hospital, Ankara, Turkey.

Hakan Apaydin (H)

Department of Internal Medicine, Division of Rheumatology, Ankara City Hospital, Ankara, Turkey. drhakanapaydin@gmail.com.

Meryem Aslan (M)

Department of Internal Medicine, Ankara City Hospital, Ankara, Turkey.

Hüseyin Çamlı (H)

Department of Internal Medicine, Ankara City Hospital, Ankara, Turkey.

Enes Seyda Şahiner (ES)

Department of Internal Medicine, Ankara City Hospital, Ankara, Turkey.

Serdar Can Güven (SC)

Department of Internal Medicine, Division of Rheumatology, Ankara City Hospital, Ankara, Turkey.

Berkan Armağan (B)

Department of Internal Medicine, Division of Rheumatology, Ankara City Hospital, Ankara, Turkey.

Selma Karaahmetoğlu (S)

Department of Internal Medicine, Ankara City Hospital, Ankara, Turkey.

Ihsan Ates (I)

Department of Internal Medicine, Ankara City Hospital, Ankara, Turkey.

Orhan Kucuksahin (O)

Department of Internal Medicine, Division of Rheumatology, Ankara City Hospital, Ankara, Turkey.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH